Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Peptide Immunotherapy in Advanced Renal Cell Carcinoma
NCT02429440Phase 2Unknown
- Sponsor
- University Hospital Tübingen
- Start
- May 2005
- Primary completion
- Oct 2017
01
Overview
Phase 2, randomised, open-label trial in renal cell carcinoma (RCC) (2 arms), sponsored by University Hospital Tübingen. Primary endpoint: Tolerability. Status: unknown.
02
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02429440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429440.